HealthCor Management’s Cytokinetics CYTK Stock Holding History

HealthCor Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$7.53M	Sell	164,440 -270,120	-62%	-$11.6M	6.91%	3
2022 Q3	$21.1M	Sell	434,560 -51,040	-11%	-$2.46M	2.63%	13
2022 Q2	$19.1M	Sell	485,600 -649,510	-57%	-$26.1M	1.92%	22
2022 Q1	$41.8M	Buy	1,135,110 +1,040,990	+1,106%	+$37M	2.79%	13
2021 Q4	$4.29M	Sell	94,120 -340,380	-78%	-$13.1M	0.23%	52
2021 Q3	$15.5M	Sell	434,500 -314,810	-42%	-$9.27M	0.67%	36
2021 Q2	$14.8M	Buy	749,310 +286,810	+62%	+$6.73M	0.59%	41
2021 Q1	$10.8M	Buy	+462,500	New	+$9.88M	0.38%	54

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

HealthCor Management's CYTK Position: Q4 2022 in Review

HealthCor Management reduced its Cytokinetics (CYTK) stake by 62% in Q4 2022, selling an estimated $11.6M and leaving 164,440 shares worth $7.53M. The position accounts for 6.91% of the portfolio, ranked #3.

HealthCor Management first reported a position in CYTK in Q1 2021 and has held it in 8 quarters since. The position peaked at $41.8M in Q1 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

HealthCor Management held 164,440 shares of Cytokinetics worth $7.53M as of Q4 2022.
HealthCor Management sold 270,120 Cytokinetics shares in Q4 2022, an estimated $11.6M.
Cytokinetics made up 6.91% of HealthCor Management's portfolio in Q4 2022, its #3 holding.
HealthCor Management first reported a position in Cytokinetics in Q1 2021 and has held it in 8 quarters since.
HealthCor Management's Cytokinetics position peaked at $41.8M in Q1 2022.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.